Skip to main content
. 2022 Nov 25;23:328–342. doi: 10.1016/j.bioactmat.2022.11.011

Fig. 2.

Fig. 2

The ability of C-EVs to target the injured spinal cord. (A) Fluorescence images of Cy5.5-labeled EVs or Cy5.5-labeled C-EVs in mice. (B) Quantification of the fluorescence intensity of lesions in mice. (C) Representative IVIS images of the spinal cord in mice treated with PBS, Cy5.5-labeled EVs or Cy5.5-labeled C-EVs. (D) Quantification of fluorescence intensity in SCI areas in vitro. (E) Representative IVIS images of anatomical organs in mice treated with PBS, Cy5.5-labeled EVs or Cy5.5-labeled C-EVs. (F) Quantification of fluorescence intensity in the indicated organs. (G) Distribution of DIO-labeled EVs and DIO-labeled C-EVs at the center of spinal cord lesions. (H, I) Colocalization analysis of Cy5.5-labeled EVs and Cy5.5-labeled C-EVs with astrocytes at the center of spinal cord lesions. *P < 0.05; **P < 0.01 (n = 3 per group).